Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Tax Provisions: 2022-2024

Historic Tax Provisions for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to -$1.0 million.

  • Amylyx Pharmaceuticals' Tax Provisions fell 151.40% to -$1.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.7 million, marking a year-over-year decrease of 48.25%. This contributed to the annual value of -$770,000 for FY2024, which is 114.67% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Tax Provisions stood at -$1.0 million for Q4 2024, which was down 518.18% from $242,000 recorded in Q1 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Tax Provisions peaked at $2.0 million during Q4 2023, and registered a low of -$1.0 million during Q4 2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Tax Provisions value was $221,000 (recorded in 2022), while the average stood at $527,500.
  • Over the last 5 years, Amylyx Pharmaceuticals' Tax Provisions had its largest YoY gain of 1,314.40% in 2023, and its largest YoY loss of 216.44% in 2023.
  • Amylyx Pharmaceuticals' Tax Provisions (Quarterly) stood at $574,000 in 2022, then spiked by 243.03% to $2.0 million in 2023, then slumped by 151.40% to -$1.0 million in 2024.
  • Its Tax Provisions stands at -$1.0 million for Q4 2024, versus $242,000 for Q1 2024 and $2.0 million for Q4 2023.